Mangoceuticals Reports Material Agreements and Asset Changes
Ticker: MGRX · Form: 8-K · Filed: May 23, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | May 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, acquisition-disposition, financial-statements
TL;DR
Mangoceuticals filed an 8-K on 5/22/25 covering material agreements, asset changes, and financial statements.
AI Summary
On May 22, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing several material events. These include the entry into and termination of a material definitive agreement, and the completion of an acquisition or disposition of assets. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including potential acquisitions or divestitures, which could impact the company's structure and future financial performance.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions like acquisitions/dispositions and material agreements, which inherently carry business risks.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- May 22, 2025 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- 001-41615 (other) — SEC File Number
- 87-3841292 (other) — IRS Employer Identification No.
- 15110 N. Dallas Parkway , Suite 600 Dallas , Texas 75248 (address) — Principal executive offices
- (214) 242-9619 (phone_number) — Registrant's telephone number
FAQ
What specific material definitive agreements were entered into or terminated by MANGOCEUTICALS, INC.?
The filing states that MANGOCEUTICALS, INC. entered into and terminated a material definitive agreement, but does not provide specific details about the agreements themselves in the provided text.
What was the nature of the acquisition or disposition of assets completed by MANGOCEUTICALS, INC.?
The filing indicates the completion of an acquisition or disposition of assets, but the specific details of the transaction are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 22, 2025.
What is the principal executive office address for MANGOCEUTICALS, INC.?
The principal executive office address for MANGOCEUTICALS, INC. is 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What is the SEC file number for MANGOCEUTICALS, INC.?
The SEC file number for MANGOCEUTICALS, INC. is 001-41615.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding MANGOCEUTICALS, INC. (MGRX).